Revelise®

Recombinant tissue plasminogen activator, a glycoprotein that is activated by binding to fibrin, which causes the conversion of plasminogen to plasmin and leads to the dissolution of the fibrin clot.

Alteplase was included in the “List of strategically important medicines, the production of which must be ensured on the territory of the Russian Federation” (Order of the Government of the Russian Federation dated July 6, 2010 No. 1141-r).

The GENERIUM is the first company in the world that has developed and registered the biosimilar of alteplase - Revelise®

ЛП-05158 от 01.11.2018